The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -20,427,683 |
| Depreciation | 32,421 |
| Amortization expense | 630,164 |
| Stock-based compensation | 297,467 |
| Change in fair value of warrant liabilities | -115,301 |
| Impairment expense | 4,162,911 |
| Realized foreign currency translation loss from dissolution of subsidiaries | -7,171 |
| Change in fair value of derivative warrant liability | 416,619 |
| Loss on asset disposal | 103,322 |
| Prepaid expenses | 60,536 |
| Other current assets | 269,278 |
| Accounts payable and accrued liabilities | 11,233 |
| Net cash used in operating activities | -15,211,490 |
| Proceeds from the sale of equipment | 11,000 |
| Net cash provided by investing activities | 11,000 |
| Payments on financed director and officer insurance | 448,279 |
| Proceeds from issuance of common stock under atm agreement, net of fees and offering costs | 2,078,348 |
| Proceeds from issuance of common stock from the exercise of pre-funded warrants, net | 871 |
| Proceeds from may 2025 public offering of common stock, net | 4,214,506 |
| Proceeds from december 2025 public offering of common stock, net | 55,424,354 |
| Issuance of common stock from the exercise of warrants, net | 2,249,000 |
| Net cash provided by financing activities | 63,518,800 |
| Effect of foreign currency translation on cash | 18,766 |
| Net change in cash, cash equivalents, and restricted cash | 48,337,076 |
| Cash, cash equivalents, and restricted cash - beginning of period | 6,922,729 |
| Cash, cash equivalents, and restricted cash - end of period | 55,259,805 |
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)